natgillin/translations-raw huggingface dataset:
converting the compound of formula (11) to compound of formula (I), optionally converting the compound of formula (I) to a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, m, n and p are as defined in claim 1. 
konvertirani spoj formule (11) u spoj formule (I), opcijsko konvertiranje spoja formule (I) do njegovih farmaceutski prihvatljivih soli; gdje su R, R1, R2, R3, m, n i p kao što je definirano u patentnom zahtjevu 1.
converting the compound of formula (10) to deprotected compound of formula (11); 
konvertiranje spoja formule (10) u deprotektirani spoj formule (11);
The process of claim 5, wherein, the compound of formula (10) is converted to the compound of formula (11) using hydrochloric acid or trifluoro acid in a solvent, for example a solvent selected from ethanol, tetrahydrofuran, toluene, acetic acid, ethyl acetate, isopropanol, diethyl ether, dichloromethane or a mixture thereof 
Postupak prema patentnom zahtjevu 5, naznačen time, da se spoj formule (10) konvertira u spoj formule (11) korištenjem klorovodične kiseline ili trifluor kiseline u rastvoru, na primjer rastvor je izabran od etanola, tetrahidrofurana, toluena, octene kiseline, etil acetata, izopropanola, dietil etera, diklormetana ili njihove mješavine.
The pharmaceutical composition as claimed in claim 7, which comprises one or more, additional agents selected from the group consisting 5-HT1-7 receptors, GABA inverse agonists and other nicotinic acetylcholine receptors. 
Farmaceutska kompozicija prema patentnom zahtjevu 7, koja sadrži jedan ili više dodatnih agenasa izabranih iz grupe koja se sastoji od 5-HT 1-7 receptora, GABA inverznih agonista i drugih nikotinskih acetilkolinskih receptora.
The pharmaceutical composition as claimed in claim 7 or claim 8, which is in the form of a tablet, capsule, powder, lozenges, suppositories, syrup, solution, suspension or an injectable, wherein said form is suitable for administration in a single dose or multiple dose units. 
Farmaceutska kompozicija prema patentnom zahtjevu 7 ili patentnom zahtjevu 8, koja je u obliku tableta, kapsula, praška, pastila, supozitorija, sirupa, rastvora, suspenzija ili je injektibilna, naznačena time što je navedeni oblik pogodan za primjenu u pojedinačnoj dozi ili višestrukim doznim jedinicama.
A compound according to claim 1, except the compound of formula (A) is not excluded, or a compound according to any one of claim 2 or claim 3, for use in the treatment of a condition selected from: depression, a cognitive memory disorder, pain or obesity. 
Spoj prema patentnom zahtjevu 1, izuzev da spoj formule (A) nije isključen, ili spoj prema bilo kojem od patentnih zahtjeva 2 ili 3, za uporabu u liječenju stanja odabranog od: depresije, kognitivnog poremećaja pamćenja, boli ili pretilosti.
A tungsten (VI) salt with a pharmaceutically or veterinarily acceptable cationic group, or a solvate thereof for use in the treatment of female infertility in non-diabetic mammals. 
Tungsten (VI) sol s farmaceutski ili veterinarski prikladnom kationskom skupinom, ili njezin solvat, za uporabu u liječenju ženske neplodnosti u sisavaca ne-dijabetičara.
The tungsten (VI) salt for use according to claim 3, where the cationic group is selected from the group consisting of sodium, potassium, magnesium and calcium. 
Tungsten (VI) sol za uporabu prema zahtjevu 3, gdje se kationska skupina odabire iz grupe koju čine natrij, kalij, magnezij i kalcij.
The tungsten (VI) salt for use according to claim 9, where the change in the hypothalamic-pituitary axis is selected from the group consisting of polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, eating disorders, obesity, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, celiac disease, chronic renal failure and idiopathic causes. 
Tungsten (VI) sol za uporabu prema zahtjevu 9, gdje se poremećaj osi hipotalamus-hipofiza odabire iz grupe koju čine sindrom policističnih jajnika, metabolički sindrom, hiperprolaktinemija, endometrioza, poremećaji hranjenja, pretilost, hipotiroidizam, multipla skleroza, reumatoidni artritis, eritematozni lupus, ciroza, celijakija, kronično zatajenje bubrega te idiopatski uzroci.
The tungsten (VI) salt for use according to claim 10, where the change in the hypothalamic-pituitary axis is due to idiopathic causes. 
Tungsten (VI) sol za uporabu prema zahtjevu 10, gdje je poremećaj osi hipotalamus-hipofiza zbog idiopatskih uzroka.
Pidotimod or a physiologically acceptable salt thereof for use according to any of the preceding claims, characterized in that it is administered in combination or in temporal proximity with at least one additional active principle. 
Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se primjenjuje u kombinaciji ili vremenski blizu najmanje jednog dodatnog aktivnog principa.
The building element according to claim 1 or 2, wherein said insulating layer is formed as a multi-layer structure comprising an inner layer of acoustic damping material and/or fire resistant material, optionally heat insulation material, and an outer layer, preferably of gypsum board. 
Zidna ploča sukladno zahtjevu 1, pri čemu je izolacijski sloj (45, 50) formiran kao višeslojna struktura koja obuhvaća unutarnji sloj (45) akustičnog materijala za prigušivanje i/ili vatrootpornog materijala, opcionalno materijala toplinskog izolatora, i vanjski sloj, poželjno od gips ploče (43).
A single-layer printing method according to claim 1, characterized in that the film-forming substance is gum arabic. 
Postupak jednoslojnog tiska prema Zahtjevu 1, naznačen time, što je supstanca za formiranje filma gumi-arabika.
A single-layer printing method according to claim 1, characterized in that the ink is applied to the wrapper for smoking articles continuously. 
Postupak jednoslojnog tiska prema Zahtjevu 1, naznačen time, što se tinta nanosi na papirni omotač za proizvode za pušenje neprekidno.
A single-layer printing method according to claim 1, characterized in that the ink is applied to the wrapper for smoking articles in straight, wavy or zigzag band form. 
Postupak jednoslojnog tiska prema Zahtjevu 1, naznačen time, što se tinta nanosi na papirni omotač za proizvode za pušenje pravocrtno, valovito ili u cik-cak obliku.
Installation (1), suitable for the testing of open, deluge fire extinguishing systems, comprising: 
Instalacija (1), prikladna za testiranje otvorenih, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara, obuhvaća:
a smoke and/or mist generator (6,7) and a connecting conduit (8), suitable and dedicated for connecting the smoke and/or mist generator to an open fire extinguishing system; wherein the generator comprises a compressor (23) and/or a pump (5) which is able to generate a gas flow of at least 18 litres per second and/or is able to generate a pressure drop of at least 0.2 bars and/or which is able to generate a smoke to be generated with an optical smoke density of at least 10 per meter. 
generator dima i/ili magle (6,7) i spojnu cijev (8), prikladnu i namijenjenu spajanju s generatorom dima i/ili magle sa sustavom za gašenje otvorene vatre; pri čemu generator obuhvaća kompresor (23) i/ili crpku (5) koja može genrirati protok plina od barem 18 litara po sekundi i/ili može generirati pad tlaka od barem 0.2 bara i/ili može generirati dim koji može biti generiran s optičkom gustoćom dima od barem 10 po metru.
Installation (1) according to claim 1, where in the installation (1) comprises a gas flow to be generated of at least 50 litres per second. 
Instalacija (1) sukladno zahtjevu 1, pri čemu instalacija (1) obuhvaća protok plina od barem 50 litara po sekundi.
Installation (1) according to claim 1 or 2, where in the installation (1) comprises a smoke with an optical smoke density of at least 20 per meters. 
Instalacija (1) sukladno zahtjevu 1 ili 2, pri čemu instalacija (1) obuhvaća dim optičke gustoće od barem 20 po metru.
Installation (1) according to any of the preceding claims, where in the smoke and/or mist generator comprises a heating element (7). 
Instalacija (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu generator dima i/ili magle obuhvaća element za zagrijavanje (7).
Installation (1) according to any of the preceding claims, wherein the installation (1) forms part of an open or deluge fire extinguishing system or is permanently installed thereon, therein or in fluid connection therewith. 
Instalacija (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu instalacija (1) formira dio otvorenog, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara ili je trajno instalirana na isti, u isti ili u fluidnoj povezanosti s istim.
Method for testing of open, deluge fire extinguishing systems, comprising the following steps to be performed in any suitable order: 
Postupak testiranja otvorenih, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara, obuhvaća sljedeće korake koji se izvode bilo kojim prikladnim redom:
providing an installation (1), preferably an installation according to claims 1-7 for generating smoke and/or mist; 
pružanje instalacije (1), poželjno instalacije sukladno zahtjevima 1-7 za generiranje dima i/ili magle;
eventually repeating of the steps b-d for any further section (16A-E) of the open or deluge fire extinguishing system. 
eventualno ponavaljanje koraka b - d (16A-E) otvorenog ili deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara.
The method according to claim 9 wherein the mass flow of the smoke is chosen such, that the exiting speed of the smoke from the spray heads (17A-E) is at least 10 meters per second and/or where in the optical smoke density is at least 1 per meter and/or where in the installation can generate a pressure drop of at least 0.2 bars. 
Postupak sukladno zahtjevu 9 pri čemu je tijek dima odabran tako, da je izlazna brzina dima iz štrcaljki (17A-E) barem 10 metara po sekundi i/ili gdje je optička gustoća dima barem 1 po metru i/ili gdje instalacija može generirati pad tlaka od barem 0.2 bara.
The method according to claims 9 or 10, wherein the reach of spray of the individual spray heads (17A-E) is being inspected, by registering the cone and/or cloud of smoke exiting from the spray head. 
Postupak sukladno zahtjevima 9 ili 10, pri čemu je doseg spreja individualnih štrcaljki (17A-E) ispitivan, registriranjem stošca i/ili oblaka dima koji izlazi iz štrcaljke.
The use of smoke and/or mist with in a network of conduits (18A-E) of a preferably open or deluge fire extinguishing system for the testing of the openness of the extinguishing system, where in the smoke comprises an optical smoke density of at least 1 per meter and/or where in the flow of the smoke being inserted in the fire extinguishing system is chosen such, that the speed of the smoke exiting from the spray heads (17A-E) of the system is at least 10 meters per second. 
Uporaba dima i/ili magle u mreži cijevi (18A-E) poželjno otvorenog ili deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara radi testiranja otvorenosti sustava za gašenje požara, pri čemu je dim optičke gustoće od barem 1 po metru i/ili gdje je u tijek dima umetnut u sustav za gašenje požara odabran tako, da brzina dima koji izlazi iz štrcaljki (17A-E) sustava je barem 10 metara po sekundi.
providing of an installation for the production of oil and/or gas; 
pružanje instalacije za proizvodnju ulja i/ili plina;
installation of an open, deluge fire extinguishing system on at least a part of the installation for the production and/or reclaiming of oil and/or gas; 
instalacija otvorenih, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara na barem dijelu instalacije za proizvodnju i/ili povrat ulja i/ili plina
testing of the open, deluge fire fighting system according to a method according to any of the claims 9-11. 
testiranje otvorenih, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara sukladno postupku iz bilo kojeg od zahtjeva 9-11.
A composition according to claim 1 wherein the average particle size of the buprenorphine is less than 20µm. 
Supstanca prema patentnom zahtjevu 1 pri čemu je prosječna veličina čestice buprenorfina manja od 20 µm.
A composition according to any claim 2 wherein the particle size of the buprenorphine is less than 10µm. 
Supstanca prema patentnom zahtjevu 2 pri čemu je prosječna veličina čestice buprenorfina manja od 10 µm.
The composition for the use according to claim 6 wherein the composition provides treatment for opioid dependence or pain relief over a period of no more than 30 days. 
Supstanca za upotrebu prema patentnom zahtjevu 6 pri čemu ova supstanca osigurava terapiju kod ovisnosti o opijatima ili ublažavanje bolova tokom perioda koji nije duži od 30 dana.
The composition for the use according to claim 8 wherein the composition provides treatment for opioid dependence or pain relief over a period of at least 10 days and no more than 17 days. 
Supstanca za upotrebu prema patentnom zahtjevu 8 pri čemu ova supstanca osigurava terapiju kod ovisnosti o opijatima ili ublažavanje bolova tokom perioda od najmanje 10 dana a ne dužeg od 17 dana.
The composition for the use according to any of claims 6 to 10 which delivers a therapeutically effective dosage of the buprenorphine or metabolite thereof from about 0.1 to about 10 milligrams (mg) or about 1 to about 8 milligrams (mg) per day. 
Supstanca za upotrebu prema bilo kojem od patentnih zahtjeva 6 do 10 koja isporučuje terapijski djelotvornu dozu buprenorfina ili njegovog metabolita od oko 0,1 do oko 10 miligrama (mg) ili oko 1 do oko 8 miligrama (mg) na dan.
The composition for the use according to any of claims 6 to 11, wherein the dosage achieves a therapeutically effective level of the buprenorphine or metabolite thereof within about one day after administration of the composition; and wherein the therapeutically effective dosage of the buprenorphine, or metabolite thereof is delivered for at least about 7 days after administration of the composition, or for at least about 30 days after administration of the composition. 
Supstanca za upotrebu prema bilo kom od patentnih zahtjeva 6 do 11, pri čemu ova doza dostiže terapijski djelotvoran nivo buprenorfina ili njegovog metabolita u roku od jedan dan posle primjene ove supstance; i pri čemu se terapijski djelotvorna doza buprenorfina, ili njegovog metabolita isporučuje tokom najmanje 7 dana poslije primjene ove supstance, ili tokom najmanje oko 30 dana poslije primjene ove supstance.
mixing the water with any further optional component 
miješanja vode s bilo kojom opcijskom komponentom
grinding the suspension until the required particle size is achieved. 
mljevenje suspenzije sve dok se ne dostigne potrebna veličina čestica.
the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 15 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, 
sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, ii) sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline, i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida iii) lipidne globule imaju volumni modalni promjer od 1.0 µm ili veći, i gdje nutritivni pripravak nije humano mlijeko.
The nutritional composition according to any one of the preceding claims wherein the lipid globules are at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje su lipidne globule barem djelomično obložene fosfolipidima na površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide.
A nutritional composition according to any one of claims 1-9 for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, increased bone mass and increased bone mineral density. 
Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesne građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti fi povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
is hydrogen or hydroxy; and 
je vodik ili hidroksi;
The composition according to claim 1, wherein the polymer has a methoxy group content of 0.35-0.70 mmol/g. 
Pripravak prema zahtjevu 3, gdje polimer ima sadržaj metoksi skupina od 0.35-0.70 mmol/g.
The composition according to claim 1, wherein the intumescent ingredient comprises an intumescent filler composition comprising an acid source, a carbon source, and a gas source. 
Pripravak prema bilo kojem od prethodnih zahtjeva, gdje bubreći sastojak obuhvaća pripravak bubrećeg punila koji sadrži izvor kiseline, izvor ugljika i izvor plina.
a matrix which consists of lipophilic compounds with melting point below 90°C, and amphiphilic compounds, in which said at least one dye is at least partly incorporated; 
matriks koji se sastoji od lipofilnih spojeva s talištem nižim od 90°C, i amfifilnih spojeva, gdje je barem jedna boja barem djelomično inkorporirana;
Composition according to the preceding claims, in form of tablet or capsule. 
Pripravak prema prethodnim zahtjevima, u obliku tablete ili kapsule.
Composition according to the preceding claims, wherein said hydrophilic compounds are compounds forming hydrogel, preferably selected from among polymers or copolymers of the acrylic or methacrylic acid, alkyl vinyl polymers, alkyl celluloses, hydroxyalkyl celluloses, carboxyalkyl celluloses, modified celluloses, plurisubstituted celluloses, polysaccharides, dextrins, pectins, starches, complex starches, starch derivatives, alginic acid, synthetic rubber, natural rubber, polyalcohol or mixtures thereof. 
Pripravak prema prethodnim zahtjevima, gdje su hidrofilni spojevi oni spojevi koji formiraju hidrogel, poželjno odabrani između polimera ili kopolimera akrilatne ili metakrilatne kiseline, alkil vinil polimera, alkil celuloza, hidroksialkil celuloza, karboksialkil celuloza, modificiranih celuloza, plurisupstituiranih celuloza, polisaharida, dekstrina, pektina, škrobova, kompleksnih škrobova, derivata škroba, alginatne kiseline, sintetičke gume, prirodne gume, poliakohola ili njihovih mješavina.
Composition according to the preceding claims, wherein said gastro-resistant coating is selected from among polymers of the acrylic or methacrylic acid, copolymers of the acrylic or Methacrylic acid, cellulose derivatives, hydroxybutyrate-based polymers, shellac or mixtures thereof. 
Pripravak prema prethodnim zahtjevima, gdje se želučanootporna ovojnica odabire između polimera akrilatne ili metakrilatne kiseline, kopolimera akrilatne ili metakrilatne kiseline, derivata celuloze, polimera na bazi hidroksibutirata, šelaka ili njihovih mješavina.
A method of injecting surface water into soil beneath a ground area (10) comprising: installing a series of elongated pumping/drainage channel members (12A, 12B) into a series of hole formed extending vertically into the ground, said members having a series of lengthwise extending channel features defined therein open to the outside of the members, said pumping/drainage channel members (12A, 12B) extending to a substantial depth below grade, whereby soil moisture tends to enter said channels formed therein and drain downwardly through said channels to inject water into the soil around said channel member lower ends, characterized by the top ends of said channel members located to be below grade and further including blocking the top end of each of said pumping/drainage channel members to create a vacuum in the channel features at the top end as water at the bottom end moves out into the surrounding soil. 
Postupak ubrizgavanja površinske vode u tlo ispod površine tla (10), koji obuhvaća: ugradnju niza izduženih crpno/drenažnih elemenata kanala (12A, 12B) unutar niza otvora formiranih da se protežu okomito u tlo, navedeni elementi imaju niz pomoćnih kanala koji se protežu uzdužno u tlo i definirajući ovdje otvore prema vanjskoj strani elemenata, navedeni crpno/drenažni elementi kanala (12A, 12B) protežu se do znatne dubine tla, pri čemu vlažnost tla ima tendenciju da prodre u spomenute kanale formirane unutra i odvodi prema dolje kroz navedene kanale za ubrizgavanje vode u tlo oko nižih krajeva navedenih elemenata kanala, naznačen time da se gornji krajevi navedenih elemenata kanala smještenih ispod površine tla i nadalje obuhvaćaju blokade gornjeg kraja svakog od navedenih crpno/drenažnih elemenata kanala kako bi se stvorio vakum u pomoćnom kanalu na gornjem kraju dok voda na donjem kraju ističe van u okolno tlo.
The method according to claim 1 wherein said members (12A, 12B) are installed extending vertically into soil. 
Postupak prema zahtjevu 1, pri čemu su navedeni elementi (12A, 12B) ugrađeni na način da se pružaju okomito u tlo.
The method according to claim 6 wherein clusters of two spaced apart shorter members (12A) and a longer member (12B) between said shorter members (12A) are installed into successive portions of said ground area. 
Postupak prema zahtjevu 6, pri čemu su skupine dvaju razmaknutih kraćih elemenata (12A) i dužeg elementa (12B) između navedenih kraćih elemenata (12A) ugrađene u uzastopnim dijelovima navedenog područja tla.
reacting a compound of formula with a compound of formula to a compound of formula wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
[image] sa spojem sljedeće formule: [image] u spoj sljedeće formule: [image] gdje su supstituenti opisani u zahtjevu 1, ili prema želji, dobiveni spojevi se pretvaraju u farmaceutski prihvatljive kiselinske adicijske soli.
wherein at least two of X2, X3 and X4 are independently a cationic subunit; and wherein the peptide is linked at its N-terminus to the conjugating group by a disulfide bond. 
gdje su barem dva od X2, X3 i X4 nezavisno kationska podjedinica; i gdje je peptid vezan na svom N-kraju disulfidnom vezom za konjugirajuću skupinu.
The compound of claim 1, wherein the peptide is 8 to 11, 8 to 10 or 8 to 9 amino acids in length. 
Spoj prema zahtjevu 1, gdje peptid po duljini ima 8 do 11, 8 do 10 ili 8 do 9 aminokiselina.
The compound of claim 4, wherein the conjugating group is cysteine where the cysteine is an N-acetylated cysteine. 
Spoj prema zahtjevu 4, gdje je konjugirajuća skupina cistein pri čemu je cistein N-acetilirani cistein.
A compound comprised of a peptide comprising the sequence carrrar (SEQ ID NO:2) and a conjugating group, said peptide linked by a disulfide bond. 
Spoj koji se sastoji od peptida koji obuhvaća sekvencu carrrar (SEQ ID NO:2) i konjugirajuće skupine, taj peptid je povezan disulfidnom vezom.
The container (22, 122, 222, 322) set forth in claim 1 wherein said lower portion (36) includes a cylindrical outer surface and at least one closure engagement feature (42). 
Spremnik (22, 122, 222, 322) u skladu s patentnim zahtjevom 1, naznačen time što navedeni donji dio (36) ima valjkastu vanjsku površinu i najmanje jedan element za učvršćivanje zatvarača (42).